Sosna, BarbaraBartusik-Aebisher, DorotaCieślar, GrzegorzKawczyk-Krupka, AleksandraLatos, Wojciech2022-04-072022-04-072021European Journal of Clinical and Experimental Medicine T. 19, z. 4 (2021), s. 322–3252544-2406http://repozytorium.ur.edu.pl/handle/item/7583Introduction. Gastroesophageal reflux disease (GERD) is a common disease with the highest prevalence in North America. Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy. Aim. The aim of this article is to complete discuss the GERD characterized by heartburn and/or regurgitation symptoms. Material and methods. We discuss here the evidence for medical therapy for PPI nonresponsive GERD. Analysis of the literature. GERD may present with a variety of other symptoms, including water brash, chest pain or discomfort, dysphagia, belching, epigastric pain, nausea, and bloating. In addition, patients may experience extraesophageal symptoms like cough, hoarseness, throat clearing, throat pain or burning, wheezing, and sleep disturbances. Conclusion. There has been an increase in GERD prevalence. GERD is one of the most common gastrointestinal disorders managed by gastroenterologists and primary care physicians.engAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowehttp://creativecommons.org/licenses/by-nc-nd/4.0/diagnosticsendoscopic treatmentgastrologyreview10.15584/ejcem.2021.4.62544-1361